BioRestorative Therapies Reports Promising Phase 2 Trial Results for Chronic Pain Treatment

BioRestorative Therapies, a regenerative medicine company, has reported encouraging results from its phase 2 clinical trial of BRTX-100, a stem cell therapy aimed at treating chronic lumbar disc disease. According to CEO Lance Alstodt, over 74% of participants showed more than 50% improvement in function, and over 72% reported a greater than 50% reduction in pain at 52 weeks, surpassing the FDA's clinically meaningful threshold of 30%. This outcome suggests a potential accelerated path to approval for BRTX-100, which differs from traditional pain management by targeting the root cause of pain rather than masking it. The company is on track to enroll 99 patients for the trial, with further announcements expected soon. For more details, watch the full interview here.